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Severe acute respiratory syndrome (SARS) is a dangerous infection with pandemic
potential. It emerged in 2002 and its aetiological agent, the SARS Coronavirus
(SARS-CoV), crossed the species barrier to infect humans, showing high morbidity
and mortality rates. No vaccines are currently licensed for SARS-CoV and important
efforts have been performed during the first outbreak to develop diagnostic tools.
Here we demonstrate the transient expression in Nicotiana benthamiana of two
important antigenic determinants of the SARS-CoV, the nucleocapsid protein (N) and
the membrane protein (M) using a virus-derived vector or agro-infiltration, respectively.
For the M protein, this is the first description of production in plants, while for plant-
derived N protein we demonstrate that it is recognized by sera of patients from the SARS
outbreak in Hong Kong in 2003. The availability of recombinant N and M proteins from
plants opens the way to further evaluation of their potential utility for the development
of diagnostic and protection/therapy tools to be quickly manufactured, at low cost and
with minimal risk, to face potential new highly infectious SARS-CoV outbreaks.
Keywords: SARS-CoV, severe acute respiratory syndrome (SARS), N protein, M protein, plant expression, disease
outbreaks, emerging infectious disease
INTRODUCTION
Recombinant proteins expressed in plants have emerged as a novel branch of the biopharmaceutical
industry and hold great potential to produce diﬀerent types of therapeutic proteins at low cost and
with reduced risks of contamination with human and animal pathogens (Moustafa et al., 2015;
Paul et al., 2015; Sack et al., 2015). Transient expression of target proteins can be easily achieved by
plant viruses or by agroinﬁltration (Gleba et al., 2007), saving the time spent in the generation
of transgenic plants, often allowing higher protein yield due to the absence of chromosomal
integration and consequently of position eﬀects (Komarova et al., 2010). Transient expression
can also be used as a means for preliminary evaluation of correct expression before starting the
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generation of transgenic plants, or related platforms, such as plant
cell cultures or microalgae (Franconi et al., 2010).
Antigen preparation plays a crucial role in the development
of a diagnostic test, and plants represent an ideal biofactory
system. The approach could be extended to other cases when
a pathogen cannot be grown in the lab or is highly virulent
and needs a methodology for fast and aﬀordable production.
Indeed, virus-speciﬁc and ‘orphan’ vaccine candidates and
therapeutics represent one of the most interesting applications
of the plant-based technology, especially when it is necessary to
produce ‘rapid response’ vaccines such as those directed against
bioterrorism agents and diseases with pandemic potential, like
inﬂuenza. The capacity for such a response has already been
demonstrated by the (four) companies involved in the US in
the production of 100 million doses of inﬂuenza vaccine a
month (Rybicki, 2014). This opens the way for the use of this
technology for other diseases such as, to name a few, Ebola
(Henao-Restrepo et al., 2015; Heymann et al., 2015), avian ﬂu
(Su et al., 2015), MERS (Al-Tawﬁq and Memish, 2015; Keener,
2015) and other viruses where the principles of the so-called “One
Health Initiative” (strategies to control diseases across species)
are important (http://www.onehealthinitiative.com/). The fact
that the epidemiology of these diseases is associated to sudden
and sometimes unforeseen contagious burst, results in an on/oﬀ
attention about, in terms of research, prevention and pharma
industry eﬀorts (Barber, 2014; LaMattina, 2014). For this reason,
tools for a quick and relatively easy scale-up may provide a
solution to such emergencies (Streatﬁeld et al., 2015).
Among emerging and re-emerging diseases, severe acute
respiratory syndrome (SARS) appeared in China in November
2002. The epidemic spread to 29 countries over 5 continents,
leading to more than 8000 infected patients globally (World
Health Organization [WHO], 2006) with a fatality rate of 9.6%
(Suresh et al., 2008). The aetiological agent of the syndrome, the
coronavirus SARS-CoV, was rapidly identiﬁed (Drosten et al.,
2003; Marra et al., 2003; Rota et al., 2003). The end of the
SARS outbreak was declared by World Health Organization
[WHO] (2003) in July, thanks to strong containment measures.
However, several local outbreaks were subsequently reported in
China, as a consequence of accidental laboratory contaminations
or infections after contact with animals infected with SARS-
CoV strains signiﬁcantly diﬀerent from those predominating in
the 2002–2003 outbreak (Peiris et al., 2004). While no eﬀective
therapy is currently available, considerable eﬀorts have been
made to develop vaccines and drugs to prevent SARS-CoV
infection, since a SARS epidemic may recur at any time in the
future (Gimenez et al., 2009; Chan and Chan, 2013). Moreover,
because of the highly contagious nature of the disease, and
since SARS-CoV has been deﬁned a potential biological weapon
(Centers for Disease Control and Prevention [CDC], 2012),
it is still important to develop eﬀective SARS-CoV sensitive
diagnostic tools (Suresh et al., 2008).
The large SARS-CoV genome, a polyadenylated RNA
of 29,727 nucleotides, encodes four major viral structural
components, the spike (S), envelope (E), membrane (M), and
nucleocapsid (N) proteins, and 16 non-structural proteins
(Bartlam et al., 2007).
The structural N protein is the most abundant protein in the
SARS-CoV virion. It is a highly basic protein of 422 amino acids
(46 kDa) of the helical nucleocapsid, playing an important role
in viral pathogenesis, replication, RNA binding, cell cytokinesis
and proliferation (Surjit and Lal, 2008). N protein has been
recognized as the preferred target for detection of SARS-CoV
infection by reverse transcription-polymerase chain reaction
(RT-PCR; Suresh et al., 2008). In addition, the WHO guidelines
for SARS diagnosis, developed during the outbreak in 2003,
suggested the use of N-based ELISA for speciﬁc IgG detection
as conﬁrmatory test of SARS-CoV infection (World Health
Organization [WHO], 2003 SARS: Laboratory diagnostic tests)
due to the ability of the host to mount an early antibody response
against the N protein (Che et al., 2004).
Furthermore, since the N protein is able to induce a long-term
cell-mediated immune response in animal models, it represents a
potential vaccine candidate as well (Roper and Rehm, 2009). To
date, the production of recombinant N protein has been achieved
in a variety of heterologous expression systems, including plants,
(Zheng et al., 2009), providing proofs of concept for its use in
vaccine formulations (Roper and Rehm, 2009). However, the
immune response in animal models (both natural and non-
natural SARS-CoV hosts) might be not useful to predict the
human immune response.
The M protein is the most abundant protein in the
SARS-CoV viral envelope. It is functionally involved in the
assembly and budding of virions from the cell. M protein
forms homo-oligomers and interacts with S, E, and N proteins
(Hogue and Machamer, 2008). It consists of 221 amino
acids (25 kDa), with a short glycosylated N-terminal domain,
three membrane-spanning domains and a long immunogenic
C-terminal cytoplasmic domain. It has been reported that rabbit
antiserum raised against recombinant M protein produced in
yeast has a potent neutralizing activity in vitro (Pang et al., 2004).
Antibodies to the M protein were detectable in convalescent
SARS patients and B-cell epitopes of the M protein have been
identiﬁed (He et al., 2005). It has also been shown that M
acts as a dominant immunogen for CTL response in humans
(Liu et al., 2010). Moreover, it has been demonstrated that
SARS-CoV M-speciﬁc memory CD4+ and CD8+ T cells were
persistent in the peripheral blood of recovered SARS patients
more than 1 year after infection (Yang et al., 2007). In a study,
where diﬀerent DNA vaccines were used, M generated the
strongest T- cell response in an animal model, and recovered
SARS patients had a long-lasting CD4+ and CD8+ memory
for the M antigen (Roper and Rehm, 2009). These data suggest
that further research should be directed toward evaluating the
potential eﬃcacy of the M antigen for vaccine and diagnostic
tools development.
In this study, we demonstrate the feasibility of using plant
transient expression systems (Potato Virus X [PVX]-mediated
infection and agroinﬁltration) to produce two SARS-CoV
antigens, the N andM proteins, as useful tools to face SARS-CoV
infection.
In particular, we demonstrated that the SARS-CoV N protein
produced in Nicotiana benthamiana is recognized by the
speciﬁc antibodies of convalescent SARS patients. Moreover, the
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expression of the SARS-CoVM protein was achieved for the ﬁrst
time in plant.
The approach to rapidly get crucial antigens by transient
expression in plants, potentially attains to other infectious, either
emerging or re-emerging, diseases (e.g., MERS, Avian ﬂu, Ebola),
that share with SARS the features of rapid outbreak burst and
need to rapidly produce diagnostic or therapeutic tools.
MATERIALS AND METHODS
Cells
Escherichia coli XL1 blue strain was used as a host for cloning and
protein expression. Cells were grown in Luria-Bertani medium
at 37◦C with shaking at 250 rpm. Agrobacterium tumefaciens
GV3101 and C58C1 strains were used to transiently express the
M protein in N. benthamiana and were grown in YEB medium
(5 g/l beef extract, 1 g/l yeast extract, 5 g/l peptone, 5 g/l
sucrose, 2 mM MgSO4) at 28◦C with shaking at 250 rpm. When
necessary, ampicillin (100 µg/ml) or kanamycin (25 µg/ml) was
added to the culture medium. HEK-293 cells were cultivated as a
monolayer in DMEMmedium with 10% fetal bovin serum (FBS)
and 50 µg/ml gentamicin at 37◦C with 5% of CO2 and relative
humidity of 94%.
DNA Manipulation for Bacterial and Plant
Expression of the SARS-CoV N and M
Proteins
The nucleocapsid (N, GenBank protein id. AAP33707.1) and
membrane (M, GenBank protein id. AAP33701.1) full-length
genes of the human SARS-CoV Frankfurt I isolate, Acc. No.
AY291315 were cloned into pCR2.1-TOPO TA Cloning vector
(Invitrogen; Carattoli et al., 2005). The inserted fragments were
cut out by digestion with BamHI-NotI and sub-cloned into the
pQE-30 (Qiagen) prokaryotic expression vector (pQE-30-N and
pQE-30-M).
The full-length N gene (1269-bp long) was
ampliﬁed by PCR on the template plasmid pQE30-N
with Pfu polymerase with the forward primer 5′-
GGCCATCGATGAATTCGGATCCATCATGAGAGGATCGC
ATCACATCC-3′ (ClaI restriction site: underlined, EcoRI
site: italic, initiation translation codon: bold) and the
reverse primer 5′-GACTTGTCGACGCGGCCGCTTA
TGCCTGAGTTGAATCAGCAG-3′ (SalI site: underlined,
NotI site: italic, stop codon: bold). For mammalian cells
expression, the PCR product was cut out by digestion with
EcoRI/NotI and inserted into the pVAX1 vector (Invitrogen). For
plant expression, the PCR product was cut out with ClaI/SalI and
cloned into the pPVX201 plant vector (Baulcombe et al., 1995).
In this vector, the full-length viral cDNA of the Potato virus
X (PVX) is inserted between the constitutive 35S promoter of
the cauliﬂower mosaic virus (CaMV 35S) and the transcription
terminator (Nos-term) of the nopaline synthase gene of
A. tumefaciens, necessary for the regulation of the viral genome
expression upon infection with plasmid DNA. Characteristic
components of the viral expression vector are the following: viral
replicase gene (RdRp); triple gene block encoding protein for
cell-to-cell movement (M1-3); viral coat protein gene necessary
for encapsidation of viral RNA (CP); coat protein sub-genomic
promoter (SgP; Figure 1A).
The full-length M gene (666-bp long) from the
pCR2.1-TOPO TA vector was ampliﬁed in two
subsequent steps. First, the forward primer 5′-
GGCCATCGATGAATTCGGATCCATCATGGCAGACAACGG
TACTATTAC-3′ (ClaI restriction site: underlined,
EcoRI site: italic, initiation translation codon: bold)
and the reverse primer 5′-GTGATGGTGATGA
TGCTCGAGTGCCTGTACTAGCAAAGCAATATT-3′ (end
of the His6 tag: italic, end of the M gene: bold) were used
to add the His6 tag at the C-terminus. Subsequently,
the same forward primer and the reverse primer 5′-
GACTTGTCGACGCGGCCGCTCAATGGTGATGGTGATG
ATGCTCG-3′ (SalI site: underlined, NotI site: italic, stop
translation codon: bold) were used in order to add restriction
sites useful for cloning.
For simplicity, we report the name of the recombinant genes
N-His6 and M-His6 as N and M genes. The puriﬁed PCR
products were cloned into the Eco RV-linearized pBlueScript
SK(+; pBS) cloning vector (Stratagene; pBS-N and pBS-M),
sequenced for authenticity and sub-cloned by ClaI-SalI in
the pPVX201 plant vector (pPVX-N and pPVX-M) or by
EcoRI/NotI in the pVAX1 vector (pVAX-N and pVAX-M).
After XL1 blue cells transformation, pPVX-N and pPVX-
M plasmid DNAs were puriﬁed (maxiprep kit, Qiagen)
for plant infection, while pVAX-N and pVAX-M plasmids
were puriﬁed with endotoxin-free puriﬁcation kits (Plasmid
Maxi kit LPS-free, Qiagen) for mammalian HEK-293 cells
transfection.
The M gene was also sub-cloned by XbaI/SalI from
the pBS-M construct into the pBI-121 plant binary vector
(Clontech Laboratories, Acc. No. AF485783), obtaining the pBI-
M construct. In this construct, the M gene is inserted between
the CaMV 35S promoter and the NOS terminator. Characteristic
components of the vector are: right and left borders (RB, LB),
gene for kanamycin resistance (NPT II) under the transcription
promoter and terminator of the nopaline synthase gene of
A. tumefaciens (Figure 6A).
The pBI-M construct, obtained by substitution of the GUS
gene with the M gene, was used to transform the GV3101 and
C58C1 strains of A. tumefaciens.
Expression and Purification of N and M
Proteins in Bacteria
The expression and puriﬁcation of the N and M proteins were
done according to standard protocols (The QIAexpressionist,
Qiagen). Since it was previously described that the M protein
is toxic in bacteria (Carattoli et al., 2005), culture growth
was performed at suboptimal temperature of 30◦C. In these
conditions, we isolated a clone able to express the M protein
in E. coli. Characterization revealed that it corresponded to a
spontaneously mutated M gene, coding for a protein carrying
the three substitutions K13 > R, F36 > L, and I160 > V
(MRLV).
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TheMRLV and the N proteins were puriﬁed by Ni-NTA aﬃnity
chromatography in denaturing conditions. For the N protein,
when puriﬁed in native conditions, imidazole concentration in
the wash buﬀer was 30 mM.
Quantiﬁcation of the N protein puriﬁed in denaturing and
native condition was performed by Coomassie stained SDS-
PAGE comparing the intensity of the band at 50 kDa to
known amount of BSA using a Chemidoc ImageLab system with
ImageLab 4.0 software (Bio-Rad).
Expression of N and M Proteins in
Mammalian Cells
HEK-293 cell line was transfected in six wells plates with the
pVAX-N or pVAX-M constructs according to standard protocols
(Eﬀectene Transfection Reagent, Qiagen). 24 h post-transfection
(pt) some wells were added with 12.5 µM of the proteasome
inhibitor MG-132. 48 h pt both samples, treated or not with
MG-132, were harvested and prepared for protein expression
analysis (immunoblotting and immunoﬂuorescence). After three
washes with cold phosphate-buﬀered saline (PBS: 21 mM
Na2HPO4, 2.1 mM NaH2PO4, 150 mM NaCl, pH 7.2) cells
were centrifuged at 800 rpm for 5′, recovered and re-suspended
in SDS-loading buﬀer (10% glycerol, 60 mM Tris-HCl pH 6.8,
0.025% bromophenol blue, 2% SDS, 3% 2-mercaptoethanol) and
boiled for 10 min.
For immunoﬂuorescence analysis, HEK 293 cells were grown
on multi-chamber glass slides and transfected at 40% of
conﬂuency. 24 h post transfection cells were washed three
times with PBS, ﬁxed with 4% paraformaldehyde for 10 min
and permeabilized with 0.1% Triton X-100 in PBS. Samples
were blocked with 5% no-fat dry milk in PBS. For detection
of the N and M proteins, cells were incubated with speciﬁc
polyclonal antibodies (pAb) validated in immuno-cytochemical
assay on SARS-CoV infected and previously described (Carattoli
et al., 2005). For N protein we used a mouse anti-N pAb,
(obtained after immunization of animals with the puriﬁed His6-
N protein produced in E. coli) at 1:800 dilution. For the M
protein we used a mouse anti-M pAb (obtained by immunizing
mice with the recombinant cytoplasmic domain, amino acids
138–222, of the M protein produced in E. coli) at 1:400
dilution. Cells were then incubated with a 1:300 dilution of
an anti-mouse biotinylated secondary antibody (GE Healthcare)
and a 1:50 dilution of Streptavidin-FITC conjugated (Sigma–
Aldrich, GmbH, Steinheim, Germany). Nuclei were counter-
stained with DAPI (2 µg/ml) in PBS. Slides were examined
using a ﬂuorescence “Axiolab Zeiss” microscope (Oberkochen,
Germany) interfaced with a Coolsnap CCD camera (Roper
Scient., Princeton, NJ, USA).
Expression of N and M Proteins in
Nicotiana benthamiana
Two leaves of N. benthamiana plants (4 week-old) were dusted
with carborundum powder and inoculated with 10 µg of
the plasmids pPVX-N, pPVX-M, or pPVX201 (empty vector,
negative control) diluted in 100 µl bi-distilled water. Plants were
also treated with 100 µl bi-distilled water (mock-infected) for
monitoring viral infection symptoms. Plants were grown under
16 h daylight at 22◦C into a containment greenhouse (bio-safety
level 2) and observed daily for PVX infection signs. Inoculated
and symptomatic leaves were harvested and stored at – 80◦C until
use.
Four week-old N. benthamiana plants were inﬁltrated with
A. tumefaciens C58C1 and GV3101 cultures harboring the pBI-M
construct that had been grown and induced as described (Kapila
et al., 1997). Plants were subsequently grown as described and the
leaf disks collected 3, 4, 5, 6, 7, and 10 days post-inﬁltration (dpi)
were homogenized with an ultraturrax in three volumes (w/v) of
SDS-loading buﬀer and boiled for 3 min.
To analyze N and M protein accumulation in plant tissues,
soluble proteins were extracted from plant material using
diﬀerent buﬀers, depending on their hydrophobic properties.
Crude plant extracts were prepared by grinding the tissue to a
ﬁne powder in liquid nitrogen. The powder was re-suspended
and homogenized with an ultraturrax in three volumes (w/v) of
PBS or, alternatively for the M protein, in one volume (w/v) of
GB buﬀer (100 mM Tris-HCl pH 8.1, 10% glycerol, 400 mM
sucrose, 5 mM MgCl2, 10 mM KCl, 10 mM 2-mercaptoethanol)
containing protease inhibitors (“complete, EDTA-free,” Roche
Diagnostics, GmbH, Mannheim, Germany). Tissue homogenates
were centrifuged at 4◦C, 12,000 × g, for 10 min. The supernatant
was transferred to a fresh tube and kept on ice (or at 4◦C) until
use and total soluble protein (TSP) content was estimated by
the Bradford assay (Bio-Rad Inc., Segrate, Italy). Pellets were re-
suspended in appropriates volumes of SDS loading buﬀer, and
prepared as described in the paragraph below, constituting the
insoluble fraction of leaf extracts.
Homogenized tissues of pPVX-N infected plants were also
used to inoculate N. benthamiana plants to propagate the
infectious recombinant PVX particles until the third round of
infection.
A small-scale puriﬁcation of plant-produced N protein was
performed. In brief, lyophilized leaf material was ground in liquid
nitrogen, re-suspended and homogenized with an ultraturrax in
8 M urea, 100 mM NaH2PO4, 1 mM Tris, pH 8.0, and incubated
for 1 h at RT with gentle shaking. Leaf material was ﬁnally
lysed on ice by sonication at 10 Hz output (10 s each) for three
times. Cell debris collected by centrifugation was discarded. The
recovered supernatant was ﬁltered (0.45 µm) and incubated for
2 h with the Ni-NTA resin. Plant N protein puriﬁcation was
performed by decreasing the pH (The QIAexpressionist). Protein
elution was obtained at pH 4.5.
Immunoblotting
For immunoblotting analysis of the N protein, plant extracts
containing 20 µg TSP and puriﬁed protein were boiled for
3 min in SDS-loading buﬀer. Immunoblotting detection of the
M protein was performed on plant extracts incubated at 40◦C for
20’ in SDS-loading buﬀer. Samples were separated by 12% SDS-
PAGE and transferred onto PVDF membranes (Immobilon-P,
Millipore). After membrane blocking with 5% non-fat drymilk in
PBS (MPBS) over night (O/N) at 4◦C,membranes were incubated
for 2 h at room temperature (RT) either with an anti-His6
monoclonal antibody (mAb; H1029-clone HIS-1, Sigma) or with
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speciﬁc polyclonal antibodies previously described (Carattoli
et al., 2005). For N protein detection, we used a rabbit anti-N
pAb, (obtained after immunization of animals with the puriﬁed
His6-N protein produced in E. coli) at 1:3000 dilution. Immune
complexes were revealed by 1 h incubation at RT with an anti-
rabbit biotinylated secondary antibody (B8895, Sigma), at 1:5000
dilution, followed by Horseradish Peroxidase (HRP)-conjugated
streptavidin (RPN1231, GE Healthcare) at 1:2000 dilution.
For M protein detection, membranes were incubated with the
mouse anti-M pAb at 1:5000 dilution, followed by incubation
with an anti-mouse HRP-conjugated secondary antibody at
1:10000 dilution (NA931, GE Healthcare).
For both proteins, the bound antibody was detected using
the ECL Plus system (“Enhanced Chemi-Luminescence”, GE
Healthcare).
Quantitative Triple Antibody Sandwich
(TAS) ELISA Assay of Leaf Extracts
The amount of N protein in the plant extracts was estimated by a
quantitative triple antibody sandwich (TAS) ELISA. Symptomatic
systemic leaves, deriving from 15 plants infected with pPVX-
N, were collected and pooled. Three independent extractions
were performed and analyzed. Microtiter plates were coated with
100 µl/well of rabbit anti-N pAb (diluted 1:3000 in PBS) for 3 h
at 37◦C followed by coating with 100 µl plant extract with a
normalized TSP content (50 µg) for 16 h at 4◦C. Wells were
then blocked with 150 µl/well of 5% MPBS at 37◦C for 3 h.
The captured N protein was detected by incubating at 37◦C
for 2 h with 100 µl/well of a 1:1500 dilution in 2% MPBS of
a mouse anti-N pAb (obtained after immunization of animals
with the puriﬁed His6-N protein produced in E. coli, Carattoli
et al., 2005) followed by incubation with 1:10000 dilution of
HRP-conjugated goat anti-mouse IgG antibody. After each step,
wells were washed three times with PBS + 0.1% Tween 20 and
one time with PBS. Enzymatic activity was measured by adding
100µl/well v/vH2O2/ABTS [2′, 2′-azino bis-(3-etilbenzotiazolin)
sulphuric acid] (KPL Inc., Gaithersburg, MD, USA) at RT in
darkness condition. The absorbance of the samples was read
after 30′ at 405 nm on an ELISA microtiter plate reader. Known
amounts of E. coli-puriﬁed N protein (0.5, 2, 5, 20, 50, 100,
and 150 ng) were used as a standard. In order to give a better
estimation of N protein yields in plant, the standard was diluted
in N. benthamiana extract.
Antigenicity Assay of the N Protein
Produced in Plant with Patient Sera
A ‘multi-strip’ western blot assay was chosen to evaluate
the antigenicity of the plant produced N protein. It is
an immunoblotting procedure modiﬁed from Kiyatkin and
Aksamitiene (2009), in which the sample, loaded in a single-well
polyacrylamide gel (a standard gel where a single preparative well
is cast), is blotted onto a membrane that is then cut into strips
of the same width, each containing same amount of protein.
Each strip is then incubated with diﬀerent antibodies or sera and
developed by a colorimetric assay (see Ciufolini et al., 1999; Di
Bonito et al., 2002).
In our experiments, single-well 12% SDS-PAGE gels were
loaded with one of the following preparations: (i) E. coli puriﬁed
N protein (7.5 µg); (ii) plant-puriﬁed N protein (3.7 µg); (iii)
plant extract from pPVX-N symptomatic leaves containing about
3.7 µg of N protein and 2 mg TSP; (iv) plant extract from
pPVX201 symptomatic leaves containing about 2 mg TSP.
Samples (iii) and (iv) were prepared as following: the powder
ground from pPVX-N or pPVX201 symptomatic leaves was re-
suspended and homogenized by an ultraturrax in one volume
(w/v) of TN buﬀer (25 mM Tris-HCl pH 7.2, 150 mM
NaCl) containing protease inhibitors. Tissue homogenates were
centrifuged at 4◦C, 15000 × g, for 15′. TSP was calculated by
Bradford assay and precipitated by trichloroacetic acid (TCA) at
25% ﬁnal concentration. After 30’ incubation in ice, samples were
centrifuged, pellets were washed with cold 80% acetone, dried,
re-suspended in SDS loading buﬀer. Gels were blotted using a
semi-dry system (BIORAD) onto PVDF membranes.
After blocking with 5% MPBS, membranes were dried at RT
and cut in 15 strips, 0.5 cm width. Each strip of samples (ii) and
(iii) contained approximately 250 ng of the N protein (as plant-
puriﬁed protein or in plant extract, respectively). As controls,
strips containing 500 ng of E. coli-produced N protein [sample
(i)], were prepared, as well as strips of plant extracts without the
N protein [extract from pPVX201 symptomatic leaves, sample
(iv)]. Before incubation with human sera, one strip from either
plant-derived or E. coli-expressed N protein was incubated with
the mouse anti-N pAb, as previously described (Carattoli et al.,
2005), to conﬁrm protein presence and to check that the amount
of protein in the strips was suﬃcient for colorimetric detection.
The strips were incubated with pools of SARS sera collected
during the SARS outbreak in Hong Kong in 2003 (Chan
et al., 2005; 86 SARS patients pooled in seven groups) at 1:100
dilution in 3% MPBS, O/N at 4◦C. Blood samples were collected
with informed written consent. The study was approved by
the institutional human research ethics committee (The Joint
Chinese University of Hong Kong–New Territories East Cluster
Clinical Research Ethics Committee).
As non-SARS controls, strips were incubated with three
pools of sera from 30 patients aﬀected by unrelated respiratory
diseases (Carattoli et al., 2005). Antigen-antibodies complexes
were revealed by a rabbit anti-human IgG (H + L) HRP-
conjugate (Southern Biotechnology Associates, Inc, Cat.No.6145-
05) diluted 1:5000 in 3% MPBS. After 1 h of incubation at RT
colorimetric reaction on the strips was induced by adding 3,3′-
Diaminobenzidine tetrahydrochloride substrate, DAB (Sigma D-
5637) and Hydrogen peroxide.
RESULTS
Expression and Purification of
Plant-Derived SARS-CoV N Protein
To produce the recombinant SARS-CoV N protein,
N. benthamiana plants (4 weeks old) were infected with the
pPVX-N DNA plasmid harboring the N gene (Figure 1A). As
a control, plants were either mock infected or infected with
the wild type pPVX201 vector. While mock infected plants
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FIGURE 1 | Potato Virus X-mediated expression of SARS-CoV N
protein in Nicotiana benthamiana plants. (A) Schematic representation of
the pPVX-N construct used for the expression of SARS-CoV N protein in
N. benthamiana leaves. CaMV 35S: constitutive 35S promoter from the
cauliflower mosaic virus; Nos-ter: transcription terminator of the nopaline
synthase gene of Agrobacterium tumefaciens; RdRp: PVX replicase gene;
M1-3: PVX triple gene block for cell-to-cell movement; CP: PVX coat protein
gene; SgP: coat protein sub-genomic promoter; N: SARS-CoV N gene;
His6-tag: histidine tag. (B) Immunoblotting of TSP extracted from
N. benthamiana plants infected with pPVX-N. For each sample, 20 µg TSP
were loaded on gel. Lane 1: N protein purified from Escherichia coli under
native conditions (40 ng); lane 2: pPVX-N inoculated leaves; lane 3: pPVX201
inoculated leaves (negative control); lane 4: pPVX-N symptomatic systemic
leaves; lane 5: pPVX201 symptomatic systemic leaves (negative control); lane
6: molecular weight marker (Magic Mark, Invitrogen); lane 7: pPVX-N
symptomatic systemic leaves extract stored at −20◦ C for 2 months.
Immunoblotting was performed with the rabbit anti-N pAb.
showed no symptoms, typical symptoms (mainly chlorotic spots)
generally appeared on the inoculated leaves of plants infected
with pPVX-N or pPVX201 vectors 4–5 days post inoculation
(dpi). The infection spread systemically to apical leaves, where
symptoms appeared 7–10 dpi.
To examine whether the N protein accumulated in infected
plants, soluble protein extracts were analyzed by ELISA and
immunoblotting.
Interestingly, after infection with the pPVX-N plasmid,
protein expression corresponded to symptoms in systemic leaves
in all plants analyzed (about 100). This result indicates that the
construct is stable and that the recombinant virus PVX-N can
spread systemically within the inoculated plant. Immunoblotting
of soluble protein extracts from plants infected with pPVX-
N reveals a single band of about 50 kDa in systemic leaves
(Figure 1B), suggesting the absence of proteolysis. On the
contrary, when the N protein is expressed in E. coli, additional
bands of lower molecular mass are present (Figure 1B).
These bands probably correspond to protein degradation, in
accordance with previous work demonstrating the intrinsic
instability and/or autolysis of this protein when expressed in
bacteria (Mark et al., 2008). Furthermore, pPVX-N-derived
extracts, stored at – 20 ◦C for 2 months and then thawed
(Figure 1B), as well as extracts obtained from freeze-dried
pPVX-N-infected leaves showed an intact N protein (data
not shown). Immunoblotting of mammalian cells transfected
with the pVAX-N plasmid also revealed the presence of a
single band of approximately 50 kDa corresponding to the N
protein (Figure 2A). Immunoﬂuorescence revealed a cytoplasmic
localization of the N protein (Figure 2B).
Plant extracts deriving from PVX-N-infected leaves were
also used for subsequent inoculations. N protein expression
was conﬁrmed at least until the third cycle of re-infection
(Supplementary Figure S1), further demonstrating the stability of
the construct and of the recombinant virion.
The amount of recombinant N protein expressed in leaves, as
measured by TAS-ELISA, was approximately 3–4 µg/g fresh leaf
weight, corresponding to 0.2% TSP (Figure 3).
Although the N protein accumulated mainly in the soluble
fraction in all the expression systems used (plant, bacteria and
mammalian cells), for puriﬁcation the best recovery of the N
protein from E. coli was obtained in denaturing conditions
(3 mg of protein/liter of culture under denaturing conditions
versus 0.4 mg protein/liter of culture under native conditions,
Figure 4A). Therefore, we decided to perform N protein
puriﬁcation in denaturing conditions also from plant tissue. We
performed a small-scale puriﬁcation by loading plant extracts
derived from freeze-dried leaves (obtained from a pool including
primary-infected and re-infected systemic leaves) on a Ni-NTA
FIGURE 2 | Expression of SARS-CoV N protein in mammalian cells.
(A) Immunoblotting of total proteins extracted from HEK-293 cells transfected
with the pVAX-N plasmid. For each sample, total proteins from 1 × 105 cells
were loaded on gel. Lane 1: N protein purified from E. coli under native
conditions (20 ng); lanes 2, 3: HEK-293 cells, 24 h post-transfection with the
pVAX-N plasmid, with or without the addition of proteasome inhibitor MG-132,
respectively; lane 4: negative control, HEK-293 cells transfected with the
pVAX empty vector. Immunoblotting was performed with the rabbit anti-N
pAb. (B) Immunofluorescence of HEK-293 cells transfected with the pVAX-N
plasmid (N) or with the pVAX empty vector [(−) CTR]. Immunofluorescence
was performed with the rabbit anti-N pAb and nuclei were counter-stained
with DAPI (100x objective, ZEISS ACHROSTIGMAT 100x/1,25 oil). Scale
Bar = 5 µm.
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FIGURE 3 | Quantification of N protein expression in pPVX-N infected
leaves by Triple Antibody Sandwich (TAS) ELISA assay. Symptomatic
pPVX-N infected systemic leaves from 15 plants were pooled and TSP
(50 µg) analyzed by TAS ELISA. Data are presented as OD405 nm values
(recorded at 30’) of the following samples: bar 1: pPVX201 infected systemic
leaves (negative control); bar 2: pPVX-N systemic leaves; bars 3–9: purified N
protein produced in E. coli (0.5, 2, 5, 20, 50, 100, and 150 ng, respectively)
diluted in N. benthamiana extract. Error bars represent standard deviations of
three technical replicates, i.e., three separate extractions from a pool of leaves
from 15 plants (pPVX201 or pPVX-N).
FIGURE 4 | N protein purification from E. coli and N. benthamiana
plants. (A) Coomassie blue-stained SDS-PAGE of the N protein purified from
E. coli by affinity chromatography. Lane 1: molecular weight marker
(Prestained Marker, Invitrogen); lanes 2–3: first and second elution fractions
(purification performed under denaturing conditions); lane 4, 5, 6: BSA 1, 2,
and 5 µg, respectively; lanes 7–8: first and second elution fractions
(purification performed under native conditions). (B) Silver-stained SDS-PAGE
of the N protein purified from N. bethamiana by affinity chromatography. Lane
1: N protein purified from E. coli under denaturing conditions (50 ng); lanes
2–3: first and second elution fractions of N protein purification from
N. benthamiana (purification performed under denaturing conditions).
aﬃnity puriﬁcation column. In this way, we obtained yields
of about 1 µg of puriﬁed N protein/g of fresh leaf weight
(Figure 4B).
Antigenicity of Plant-Derived SARS-CoV
N Protein
The ELISA and immunoblot analysis gave a ﬁrst indication of
antigenic features of the plant-derived N protein. In fact, in such
analysis the N protein was speciﬁcally recognized by rabbit and
mouse anti-His6-N hyper-immune sera that had previously been
shown to recognize the N protein in SARS-CoV infected cells
(Carattoli et al., 2005).
To further characterize the N protein expressed in plant, we
analyzed its reactivity with sera from SARS patients, collected
during the SARS outbreak in Hong Kong in 2003. These SARS
sera were previously screened by an ELISA assay with an E. coli-
expressed N protein (Di Bonito and Chan, data not shown).
Here, to evaluate SARS-positive sera reactivity with N plant
expressed protein, we used a ‘multi-strip’ western blot assay. In
a ﬁrst experiment, we evaluated the reactivity of the puriﬁed N
protein with a pool of 5 SARS sera. As shown in Figure 5A, both
preparations of puriﬁed N protein, from E. coli and from plant,
are recognized by SARS sera as well as by the mouse anti-N pAb
(positive control). Then, we validated the results obtained for the
plant-puriﬁed N protein analyzing its reactivity with other six
groups of SARS sera deriving from 86 patients and with three
groups of sera from 30 patients aﬀected by non-SARS respiratory
diseases (Figure 5B). In this experiment, we observed that the N
protein puriﬁed from plant is speciﬁcally recognized by all the
groups of SARS sera analyzed, while no reactivity was observed
with sera from patients aﬀected by other respiratory diseases.
We also tested the reactivity of SARS and non-SARS sera
with the unpuriﬁed N protein (soluble extract of pPVX-N
symptomatic leaves) and with the extract from plant infected
with the pPVX201 empty vector. A light reactivity with SARS
sera was observed only for the unpuriﬁed N protein, while no
reactivity was observed for the same preparation when using non-
SARS sera (Supplementary Figure S2). Importantly, the pPVX201
leaf extract did not react with any human sera (Supplementary
Figure S2).
To our knowledge, this is the ﬁrst report of the antigenic
properties of a plant-derived N protein as revealed by direct
serology using SARS patient sera, suggesting its possible use for
the development of SARS diagnostic assays.
Expression of Plant-Derived SARS-CoV
M Protein
We investigated the ability of plant expression systems to cope
with the synthesis of M protein. We started our studies on M
protein expression in N. benthamiana plants (4-week old) by
infection with the pPVX-M plasmid harboring the M gene as
described for the N protein. Also in this case typical symptoms
generally appeared 4–5 dpi on inoculated leaves and 7–10 dpi
on systemic leaves. However, M protein production was reported
in just 2 plants out of 100 analyzed at detectable levels (data not
shown).
Hence, we investigated the possibility to obtain the M protein
by agroinﬁltration. N. benthamiana leaves were inﬁltrated with
A. tumefaciens suspensions (strains C58 and GV3101) harboring
the pBI binary vector containing the M gene (pBI-M vector,
Figure 6A). With this simple technology, and without the use
of any post-transcriptional gene silencing suppressors, we were
able to detect SARS-CoV M protein production in plant. The
time course experiment revealed that the M protein is expressed
mainly at 4 and 5 dpi (data not shown). For immunoblotting
analysis, the M protein was extracted with an appropriate buﬀer
(GB buﬀer) and, since it was previously reported that boiling
causes M protein aggregation and precipitation (Lee et al.,
2005), samples boiling was avoided. Interestingly, the M protein
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FIGURE 5 | Antigenicity of the N protein produced in plant by reaction
with SARS patient sera. (A) Reactivity of the N protein produced in plant
and in E. coli with SARS patient sera. Strips 1, 3: purified N protein produced
in E. coli (500 ng); strips 2, 4: purified N protein produced in plant (250 ng).
Strips 1 and 2: probed with a pool of 5 SARS patient sera. Strips 3 and 4:
probed with the mouse anti-N pAb (positive control). (B) Validation of the
results shown in panel A for the N protein produced in plant. Each strip
derives from the blotting of a single-well SDS-PAGE gel (showed in C) loaded
with 3.7 µg of purified N protein produced in plant. Each strip contains
approximately 250 ng of N protein. Strip 1 was probed with the mouse anti-N
pAb (positive control). Strips 2–7: probed with SARS patient sera (different
pools deriving from several SARS patients). Strips 6–8: probed with pools of
sera deriving from patients affected by non-SARS respiratory diseases
(negative control). (C) Replica gel of the experiment shown in panel B stained
by Coomassie Brilliant Blue for loading control of the purified N protein from
plant.
FIGURE 6 | Agrobacterium-mediated expression of SARS-CoV M
protein in N. benthamiana plants. (A) Schematic representation of the
construct used for agroinfiltration. CaMV 35S: cauliflower mosaic virus
constitutive 35S promoter; NOS-ter: transcription terminator of the nopaline
synthase gene of A. tumefacien; RB, LB: right and left borders; NPT II: gene
for kanamycin resistance. (B) Comparison of M protein expression in plant by
PVX-mediated infection or by agroinfiltration and solubility (western blot
analysis of 40 µg TSP). Lane 1: molecular weight marker (Magic Mark,
Invitrogen); lanes 2, 3: soluble and insoluble fractions, respectively, from
symptomatic systemic leaves infected with pPVX-M; lanes 4, 5: soluble and
insoluble fractions, respectively, from leaves infiltrated with A. tumefaciens
C58C1/pBI-M; lanes 6, 7: soluble and insoluble fractions, respectively, from
leaves infiltrated with A. tumefaciens GV3101/pBI-M. (C) Comparison of M
protein expression in E. coli or plant (western blot analysis of 20 µg TSP).
Lane 1: purified MRLV protein produced in E. coli (20 ng; purification performed
under denaturing conditions); lane 2: leaves infiltrated with A. tumefaciens
C58C1/pBI-M; lane 3: molecular weight marker (Magic Mark, Invitrogen); lane
4: negative control, leaves infiltrated with A. tumefaciens/pBI121 empty
vector. (B) and (C): immunoblotting performed with the mouse anti-M pAb.
accumulated almost totally in the soluble fraction of the plant
extract (Figure 6B). As described in the previous paragraph
for the N protein, to better characterize the plant-derived M
protein we worked, at the same time, on M protein expression
in bacteria and mammalian cells. Due to toxic properties of M
protein for E. coli (Carattoli et al., 2005), we performed colony
selection and M protein expression under sub-optimal growth
conditions (30◦C). In this way, the M protein, with a mass of
about 25 kDa was puriﬁed by Ni-NTA aﬃnity chromatography in
denaturing conditions, obtaining yields of about 100 µg/l culture
(data not shown). DNA sequence analysis revealed the presence
in the M gene of three spontaneous point mutations: R13 > K
in the N-terminal domain, L36 > F in the ﬁrst transmembrane
domain and V160 > I in the cytoplasmic domain (MRLV). As
the plant-derived recombinant M protein, the MRLV was also
speciﬁcally recognized by the mouse anti-M pAb (Figure 6C)
that had previously validated by Immunoﬂuorescence Antibody
Assay (IFA) in SARS CoV infected Vero cells (Carattoli et al.,
2005). Although we were not able to express the M protein with
its original aa sequence in bacteria, the MRLV protein was useful
as standard for the plant-produced M protein characterization.
Immunoblotting revealed that, contrary to prokaryotic cells,
the plant system allowed the expression of the full-length M
protein, especially by the use of the Agrobacterium C58C1 strain
(Figure 6B). The M protein yield, calculated by immunoblotting
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using the quantiﬁed MRLV protein puriﬁed from E. coli as
standard, was estimated to be 0.1–0.15% TSP. The mobility of the
plant-derived M protein in SDS-PAGE was reduced compared
to the mutated bacterial form (Figure 6C), suggesting a higher
molecular mass of plant-expressed compared to the E. coli-
expressed M protein.
No attempts to purify the M protein from plant were done due
to the expression estimates.
The M protein was also expressed in mammalian cells.
Immunoﬂuorescence on M-transfected HEK-293 cells using
the mouse anti-M pAb revealed that M protein is primarily
localized in the plasma membrane (Figure 7). Similar results
were previously reported by Tseng and collaborators (Tseng
et al., 2010), who described a perinuclear and plasma membrane
localization of the M protein expressed in various cell lines.
However, we did not observe M protein expression by
immunoblotting, either in transfected cells or in the culture
medium (not shown), probably because of its low expression
level, as we reported in N. benthamiana plants by PVX-mediated
infection.
DISCUSSION
The importance to develop eﬀective therapeutic and preventive
strategies, to be readily applied to new emergent pathogens is
established by the two novel coronaviruses that have emerged
in humans in the twenty-ﬁrst century: severe acute respiratory
syndrome coronavirus (SARS-CoV) and Middle East respiratory
syndrome coronavirus (MERS-CoV). Both viruses cause acute
respiratory distress syndrome and are associated with high
mortality rates. There are no clinically approved vaccines or
antiviral drugs available for either of these infections, thus their
development represents a research priority (Graham et al., 2013).
Severe acute respiratory syndrome coronavirus was the
ﬁrst massive infectious disease outbreak and it still has the
potential to cause large-scale epidemics in the future. The key
to preventing and controlling a future outbreak of SARS is to
develop rapid and speciﬁc diagnostic methods so that suspected
FIGURE 7 | Expression of SARS-CoV M protein in mammalian cells.
Immunofluorescence of HEK-293 cells transfected with the pVAX-M plasmid
(indicated as M) or mock-transfected [pVAX empty vector, indicated as (−)
CTR]. Immunofluorescence was performed with the mouse anti-M pAb and
nuclei were counter-stained with DAPI (100x objective, ZEISS
ACHROSTIGMAT 100x/1,25 oil). Scale Bar = 5 µm.
patients can be correctly assessed. Moreover, eﬀective and safe
treatment/vaccination will be extremely important inminimizing
the damage of a new pandemic. Enormous eﬀorts have been
undertaken to these purposes. The four major diagnostic
methods available for SARS include viral RNA detection by RT-
PCR, virus induced antibodies by immunoﬂuorescence assay
(IFA), or by enzyme linked immunosorbent assay (ELISA) of
nucleocapsid protein (N) and inoculation of patient specimens
in cell culture (World Health Organization [WHO], 2003 SARS:
Laboratory diagnostic tests).
The SARS-CoVN protein, expressed at early stage of infection
and triggering a strong antibody response by the host, is
considered to be the best diagnostic target (Surjit and Lal,
2008). Plasmon resonance-based biosensors (Huang et al., 2009;
Park et al., 2009) and nanowire/carbon nanotube transistors
(Ishikawa et al., 2009) have been developed for the detection
of SARS-CoV N protein in patient sera. Such sensors oﬀer
real-time detection of nanomolar concentrations of the protein.
Nevertheless, SARS tests should also have other useful features
such as cost-eﬀectiveness and ease of operation. Moreover,
combinations of antigens may be necessary to provide a deﬁnitive
diagnosis of SARS in humans and susceptible animals (Roper and
Rehm, 2009).
The production of recombinant N protein has been achieved
in a variety of heterologous expression systems. A synthetic
gene with optimized codons has been expressed in E. coli at
high yield (Das and Suresh, 2006) but it was demonstrated
that bacterially expressed N protein produces false seropositivity
owing to interference of bacterially derived antigens (Leung
et al., 2006; Yip et al., 2007; Surjit and Lal, 2008) or cross-reacts
with antisera of human coronaviruses (HCoV-OC43 and HCoV-
229E)- infected patients (Woo et al., 2004). An interesting study
correlated the phosphorylation state of the N protein with its
antigenicity and speciﬁcity of antibodies recognition (Shin et al.,
2007). These data underline the importance of producing the
recombinant protein in eukaryotic platforms such as insect cells,
yeast, or plants to set up more eﬃcient and speciﬁc diagnostic
tests. To date, it was demonstrated that the N protein produced in
insect cells may be useful for the development of highly sensitive
and speciﬁc assays to determine SARS infection (Shin et al.,
2007). Later, the N protein was transiently expressed in plant by
agroinﬁltration, and its antigenicity was demonstrated in mice
(Zheng et al., 2009) giving a proof of concept of its use in vaccine
formulations. Previously, the S1 domain of SARS-CoV S protein
had been stably expressed in tomato and low-nicotine tobacco
plants obtaining about 0.1% TSP (Pogrebnyak et al., 2005). The
plant-derived antigen was able to induce systemic and mucosal
immune responses in mice.
While previous works have primarily focused on the S and
N proteins, there is growing evidence of the potential of the M
antigen both as an eﬀective vaccine and diagnostic candidate.
Thus, the obtainment of the recombinant full-length M protein
in an eukaryotic expression system also represents a good way
to develop an eﬀective and safe SARS-CoV vaccine. In addition
to the knowledge that the M protein elicits a strong humoral
responses, and that a speciﬁc humoral and cellular immune
response can be obtained by co-expressing S, M and E (Lu et al.,
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2007), it has been demonstrated that the M protein also contains
T cell epitopes (Liu et al., 2010). The availability of recombinant
M protein, in combination with other viral proteins might
overcome the concern about the sensitivity and the speciﬁcity
of N nucleoprotein-based assay, as described when using the N
and the S proteins together (Woo et al., 2004; Haynes et al., 2007;
Gimenez et al., 2009). This would help the development of more
eﬃcient reagents to detect antibodies in the infected human host.
Here, we propose the use of plants as an alternative system to
produce the N and M antigens that could be useful to formulate
new vaccines and diagnostic assays against SARS.
Since plant transformation and regeneration of stable
transformants require considerable time, we used transient
expression systems (PVX and agroinﬁltration) to evaluate the
ability of the plant expression system to cope with the synthesis
of the SARS-CoVM and N proteins.
The N and M full-length genes of the human SARS-CoV
Frankfurt I isolate were cloned, without codon optimization, into
diﬀerent expression vectors. For the SARS-CoV N protein, we
assessed the successful ectopic expression in N. benthamiana
plants by pPVX-mediated infection (Figure 1). We were able
to obtain the N protein in systemic leaves in most primary-
infected plants as well as in 100% re-infected plants. These results
demonstrate the stability of the construct, a condition not easily
obtained especially when large sequences are inserted in the
pPVX-derived expression cassette (the N gene is about 1300 bp).
In fact, several studies report that the use of ‘ﬁrst generation’ plant
viral vectors (like the pPVX series) for the expression of proteins
in plants can lead to insert elimination by natural selection over
replication cycles as early as the ﬁrst infection passage with a
positive correlation between insert length and elimination rate
(Avesani et al., 2007).
Unlike the observed prokaryotic expression pattern, no
proteolysis products were detected in immunoblotting by using
polyclonal sera in pPVX-N-derived extracts, fresh or stored at –
20◦C for 2 months (Figure 1B). These data demonstrate the
stability of the recombinant N protein when transiently expressed
in N. benthamiana. The same stability was observed when the N
protein was expressed in mammalian cells, even in the absence of
proteasome inhibitor (Figure 2A).
The puriﬁed plant-produced N protein is speciﬁcally
recognized by sera from Chinese SARS patients of the 2003
outbreak, and not from patients aﬀected by unrelated respiratory
diseases (Figure 5). This result suggests that the plant-expressed
SARS-N protein is suitable in SARS diagnosis.
It is interesting to note that, when using crude plant extracts,
SARS human sera reveal a weak band, corresponding to the
molecular weight of the N protein, without any cross-reaction
with other components of the plant extract (Supplementary
Figure S2). Taken together, the results indicate that plant-derived
N protein is speciﬁcally detected by antibodies of SARS patients,
using an assay where the antigen-antibody complex is revealed
by a colorimetric method, less sensitive but more speciﬁc and
suitable for hospital clinical laboratories. It should be noted that
the only information available to date about plant-derived SARS-
CoV N protein antigenicity were from Zheng et al. (2009) who
immunized mice and evaluated the impact on the regulation of
cytokines and on the elicited IgG subclasses. Our study is the ﬁrst
demonstration by direct serology that plant-derived N protein
is able to reveal human N-speciﬁc antibodies present in sera of
SARS patients, thus providing an adequate instrument to develop
a rapid, low-cost, immune-based diagnostic assay to be used as an
alternative or in association to molecular diagnosis.
For the M protein, we obtained a spontaneously mutated
MRLV protein in E. coli. This allowed to overcome toxicity of
the wild type protein when expressed in bacteria (Carattoli et al.,
2005) and to purify the MRLV protein that was then used as
positive control in our experiments. As the SARS-CoVM protein
is diﬃcult to express in recombinant form, the exact structure and
function of the protein are not fully elucidated (Neuman et al.,
2011; Tseng et al., 2013; Siu et al., 2014).
Unlike prokaryotic cells, the plant system allowed the
expression of the full-length M protein by using A. tumefaciens
(in particular the strain C58C1), demonstrating for the ﬁrst time
the possibility to express the SARS-CoV M protein in plants,
without the need of codon optimization or addition of any further
modiﬁcations. On the contrary, by PVX-mediated infection we
observed very low expression levels for the M protein, only in
2 plants out of 100 analyzed. We can speculate that membrane
M protein, that already proved to be toxic in E. coli, may be
diﬃcult to express by using a ‘living vector’ like PVX due to
interference with virus replication and/or expression/assembly
of viral components, while it is tolerated by the plant when
expressed by agro-inﬁltration.
Compared to the mutated MRLV protein produced in E. coli,
the M protein produced in plant shows a reduced electrophoretic
mobility, suggesting a higher molecular mass (Figure 6C). The
reason for this diﬀerence remains to be elucidated, but it could
be due to modiﬁed residues in the MRLV protein or by the
presence of glycosylation in the M protein produced in the
eukaryotic system (the native protein is N-glycosylated at the
fourth residue).
The plant-produced M protein yields were not suﬃcient to
perform the test with human sera. Thus, for plant-derived M
protein characterization, eﬀorts should be made in order to
enhance expression yields. This includes the use of second-
generation viral vectors (Gleba et al., 2007) or other implemented
platforms that have been developed in the last years (Moustafa
et al., 2015; Paul et al., 2015; Sack et al., 2015).
CONCLUSION
Our results add further insights to the characterization of the
N and M proteins and provide a proof of principle for using
plants as a robust, rapid and ﬂexible production system for
protein reagents suitable to face potential recurring SARS-CoV
outbreaks.
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